Magazine Article | September 1, 2015

Corbus Pharmaceuticals: Flipping The Off Switch In Rare, Chronic Inflammatory Diseases

Source: Life Science Leader
wayne koberstein

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Flipping the off switch in rare, chronic inflammatory diseases.

Corbus has the CB2-agonist Resunab (ajulemic acid) in development for three rare, chronic inflammatory indications: cystic fibrosis, systemic sclerosis, and dermatomyositis. The small-molecule compound is a “repurposed pharmaceutical.” The drug triggers the mechanism or pathway by which inflammation returns to homeostasis (resolution of inflammation), allowing damaged tissue to heal. Phase 2 trials have begun in all three indications.